Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers

Inclusion Criteria: * Subjects with colonised/ local infection in a venous leg ulcer or mixed leg ulcer with an ABPI ≥ 0,8 and \< 1.3 * A history of an appropriate compression therapy for at least 2 weeks prior to randomisation * Subjects with colonised/local infection presenting with three of five following specified signs: * pain between dressing changes * exuding wounds * erythema on peri-wound skin * oedema * odour * An ulcer size of at least 4 cm2 and a maximum size witch could be covered by one investigational product of 15x15 cm. * Ulcer duration 6 weeks to 1 year * In case of multiple ulcers: target ulcer must be at least 3 cm distant from other ulcers. * Both gender with an age ≥ 18 years * Signed informed consent Exclusion Criteria: * \> 10% necrotic (black) or fibrinous (yellow) tissue covering the wound bed * Infected wounds in need of systemic antibiotic treatment * Use of anti-microbial dressings or topical agents such as antiseptics, local antibiotics and steroids within 7 days from inclusion on the wound intended to be included * Previous treatment with silver product 2 weeks prior to inclusion * Previous treatment with MepilexAg® on the target ulcer * Use of systemic antibiotics for any reason during the previous 7 days * Venous surgery 2 weeks prior to inclusion or planned surgery within 8 weeks after inclusion * Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer/malignancy and severe anaemia) judged by the investigator to be a potential interference in the wound evaluation * Subjects with poorly controlled diabetes mellitus i.e. HbA1c \>8% * Subjects treated with systemic immunosuppressive or glucocorticosteroids, except subjects taking occasional doses or doses less than 10mg prednisolon/day or equivalent. Subjects inhaling glucocorticosteroids for asthma should not be excluded. * Known allergy/hypersensitivity to any of the components of the investigation products. * Subjects with physical and/or mental conditions that are not expected to comply with the investigation due to poor medical condition * Participation in other clinical investigation(s) within 1 month prior to start of the investigation. * Previously randomised to this investigation. * Life expectance of the subject less than 3 months * Pregnant or breast-feeding women